Study of Gecacitinib for GVHD after ruxolitinib fails
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called Gecacitinib for people who have acute graft-versus-host disease (a serious complication after a stem cell transplant) that did not get better with the standard second-line treatment, ruxolitinib. The goal is to see if Gecacitinib can help control the GVHD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stem cell transplant from any donor type (related, unrelated, or half-matched).
- Your donor cells have fully engrafted (your blood counts have recovered).
- Your acute GVHD did not improve, got worse, or caused side effects with ruxolitinib treatment.
- You can swallow tablets and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests a new oral medication called Gecacitinib for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose cGVHD is not fully controlled or requires long-term steroids. It aims to see if Gecacitinib can help manage symptoms and reduce steroid use.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This trial tests whether the drug gecacitinib can help prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant in people with myelofibrosis, a rare bone marrow disorder.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hear when a new Acute Graft Versus Host Disease Grade II-IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.